This review summarises a webinar presentation by Dr Ryan Paul in August 2021 on the role of dulaglutide, a subcutaneous once-weekly glucagon-like peptide-1 receptor agonist (GLP1RA), in diabetes management. This presentation was organised by the Goodfellow Unit using funding provided by Lilly.
Please login below to download this issue (PDF)